Kymera Therapeutics (NASDAQ:KYMR) Stock Rating Upgraded by Morgan Stanley
Kymera Therapeutics (NASDAQ:KYMR – Get Free Report) was upgraded by equities research analysts at Morgan Stanley from an “equal weight” rating to an “overweight” rating in a note issued to investors on Tuesday, Marketbeat reports. The firm presently has a $79.00 target price on the stock, up from their prior target price of $49.00. Morgan […]
Kymera Therapeutics (NASDAQ:KYMR – Get Free Report) was upgraded by equities research analysts at Morgan Stanley from an “equal weight” rating to an “overweight” rating in a note issued to investors on Tuesday, Marketbeat reports. The firm presently has a $79.00 target price on the stock, up from their prior target price of $49.00. Morgan […]
